Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation
自适应神经刺激步态冻结的神经和运动学特征
基本信息
- 批准号:9360002
- 负责人:
- 金额:$ 19.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-30 至 2018-10-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAdverse eventAlgorithmsBradykinesiaBrainBrain regionCell NucleusCessation of lifeClinicalCollectionComplementComplicationComputer softwareCouplingCustomDataDeep Brain StimulationDorsalElectrodesEmerging TechnologiesFDA approvedFall injuryFeasibility StudiesFreezingFrequenciesGaitGap JunctionsGoalsHumanImplantIndependent LivingInvestigationKnowledgeLeadLocationMachine LearningMeasurementMeasuresMedicineMotorOutcomeOutputParkinson DiseasePatientsPharmaceutical PreparationsPhasePilot ProjectsResearchRestSafetySideSignal TransductionSiteStructure of subthalamic nucleusTechnologyTelemetryTestingTimeTremorUnited StatesVariantWalkingWireless Technologycohortcomparative efficacycomputerizedeffective therapyexperienceexperimental studyfallshuman subjectimprovedkinematicsmotor disorderneuroregulationneurotransmissionnew technologypatient safetyplace fieldsrelating to nervous systemsafety and feasibilitysafety testingsensorspatiotemporalstandard care
项目摘要
PROJECT SUMMARY
Freezing of gait (FOG) in Parkinson’s disease (PD) results in unpredictable episodes of gait cessation, which
may lead to falls, injury, a loss of independent living, and even death19. The treatment of FOG is inconsistent
with either dopaminergic medication or with current open loop, continuous high frequency deep brain
stimulation (cDBS)15, 25. Emerging technology using non-continuous, closed loop or adaptive DBS (aDBS), has
the potential to improve treatment for FOG. Adaptive DBS can sense patient specific neural and/or kinematic
signals and respond by adjusting DBS parameters to provide more efficacious therapy while reducing adverse
side effects known to occur with cDBS. The critical barriers of using aDBS for FOG are the lack of knowledge
of: the neural features of FOG that could be ‘sensed’ by aDBS to trigger stimulation, the optimal, patient
specific DBS parameters for the treatment of FOG, and whether aDBS for FOG is safe and tolerable in human
PD patients. In the Bronte-Stewart Lab, we have the technology, the regulatory approvals and the research
experience collecting synchronized neural and quantitative kinematic signals, applying different DBS
parameters for FOG, performing the first aDBS experiments in freely moving PD subjects. The Bronte-Stewart
Lab was the first group and Stanford was the first site in the United States to implant a sensing neurostimulator
for PD, the Activa® PC+S (Medtronic Inc., FDA IDE/Stanford IRB approval, October 2013). This comprised the
FDA approved neurostimulator (Activa PC®, Medtronic Inc.) with additional software that enabled recording of
brain signals via telemetry from the neurostimulator itself. We have implanted twenty PD patients (largest
cohort in the world), from whom we have been collecting synchronized neural and computerized kinematic
signals for over thirty months without adverse events. We will use this new technology in conjunction with our
expertise in quantitative kinematics and validated measure of FOG to begin understanding the neural features
associated with FOG. In addition, we will use quantitative measures of FOG to accurately determine the
efficacy of patient specific stimulation parameters for effective and consistent treatment of FOG. No center
has had the technological capability to test the safety and feasibility of aDBS for FOG in freely moving
PD patients. Whether patients can tolerate aDBS, which continually adjusts output to control a time-varying
patient-specific neural signal as they are walking and moving freely is completely unknown and will be
assessed in a pilot study in this proposal. This project is expected to signal the beginning of a new era of
precise medicine: the possibility to treat FOG in PD in a customized, adaptive manner, while
minimizing adverse effects and complementing the treatment of other disabling motor features of PD
such as tremor.
项目摘要
帕金森病(PD)患者的步态冻结(FOG)会导致不可预测的步态停止发作,从而
可能导致福尔斯跌倒、受伤、丧失独立生活能力,甚至死亡19。FOG的治疗不一致
使用多巴胺能药物或使用电流开环、连续高频脑深部
刺激(cDBS)15,25.使用非连续、闭环或自适应DBS(aDBS)的新兴技术,
改善FOG治疗的潜力。自适应DBS可以感测患者特定的神经和/或运动学
通过调整DBS参数发出信号并做出响应,以提供更有效的治疗,同时减少不良反应
cDBS已知的副作用。将aDBS用于FOG的关键障碍是缺乏知识
的:FOG的神经特征,可以被aDBS“感知”以触发刺激,最佳的,患者
治疗FOG的特定DBS参数,以及aDBS治疗FOG在人体中是否安全和可耐受
PD患者。在勃朗特-斯图尔特实验室,我们有技术,监管批准和研究
经验收集同步神经和定量运动信号,应用不同的DBS
FOG参数,在自由移动的PD受试者中进行第一次aDBS实验。勃朗特-斯图尔特
实验室是第一个小组,斯坦福大学是美国第一个植入感知神经刺激器的地点
对于PD,Activa® PC+S(Medtronic Inc.,FDA IDE/斯坦福大学IRB批准,2013年10月)。这包括
FDA批准的神经刺激器(Activa PC®,Medtronic Inc.)通过附加软件,
通过神经刺激器本身的遥测技术发出大脑信号。我们已经植入了20名PD患者(最大
队列中的世界),从他们那里我们一直在收集同步神经和计算机化的运动
信号超过30个月,无不良事件。我们将使用这项新技术,
定量运动学和有效FOG测量方面的专业知识,开始了解神经特征
与FOG相关。此外,我们将使用FOG的定量测量来准确地确定
患者特定刺激参数对有效和一致治疗FOG的功效。没有中心
具有测试aDBS用于FOG自由移动的安全性和可行性的技术能力
PD患者。患者是否能够耐受aDBS,持续调整输出以控制时变
当患者自由行走和移动时,患者特异性神经信号是完全未知的,
在这项建议的试点研究评估。该项目预计将标志着一个新时代的开始,
精确医学:以定制的适应性方式治疗PD中FOG的可能性,
最大限度地减少不良反应,并补充PD的其他致残性运动特征的治疗
例如震颤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Helen Bronte-Stewart其他文献
Helen Bronte-Stewart的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Helen Bronte-Stewart', 18)}}的其他基金
Neurostimulation of the Nucleus Basalis of Meynert for the cognitive-motor syndrome in Parkinson's disease
梅纳特基底核神经刺激治疗帕金森病认知运动综合征
- 批准号:
10686249 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
Neurostimulation of the Nucleus Basalis of Meynert for the cognitive-motor syndrome in Parkinson's disease
梅纳特基底核神经刺激治疗帕金森病认知运动综合征
- 批准号:
10510424 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait using Neural and Kinematic Feedback
利用神经和运动学反馈进行双边闭环深部脑刺激以冻结步态
- 批准号:
10670150 - 财政年份:2019
- 资助金额:
$ 19.63万 - 项目类别:
Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait using Neural and Kinematic Feedback
利用神经和运动学反馈进行双边闭环深部脑刺激以冻结步态
- 批准号:
10218278 - 财政年份:2019
- 资助金额:
$ 19.63万 - 项目类别:
Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait using Neural and Kinematic Feedback
利用神经和运动学反馈进行双边闭环深部脑刺激以冻结步态
- 批准号:
10455532 - 财政年份:2019
- 资助金额:
$ 19.63万 - 项目类别:
THE DURATION OF THERAPEUTIC EFFECT OF DEEP BRAIN STIMULATION PARKINSON'S
脑深部刺激帕金森病治疗效果的持续时间
- 批准号:
7605170 - 财政年份:2007
- 资助金额:
$ 19.63万 - 项目类别:
THE DURATION OF THERAPEUTIC EFFECT OF DEEP BRAIN STIMULATION PARKINSON'S DISEASE
脑深部刺激帕金森病治疗效果的持续时间
- 批准号:
7375206 - 财政年份:2005
- 资助金额:
$ 19.63万 - 项目类别:
THE DURATION OF THERAPEUTIC EFFECT OF DEEP BRAIN STIMULATION PARKINSON'S DISEASE
脑深部刺激帕金森病治疗效果的持续时间
- 批准号:
7202041 - 财政年份:2004
- 资助金额:
$ 19.63万 - 项目类别:
Duration of therapeutic effect of deep brain stimulation
脑深部刺激治疗效果的持续时间
- 批准号:
6980924 - 财政年份:2003
- 资助金额:
$ 19.63万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 19.63万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 19.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 19.63万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 19.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 19.63万 - 项目类别:
Studentship